Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00derivedno prior Q2 2021 on file Net Income-$5.16M-$5.16MN/M vs Q2 2021 EPS Diluted-$0.32-$0.32N/M vs Q2 2021 Operating Income-$5,171,748N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,330,513N/M ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end